Japan's AnGes begins phase 2/3 clinical trial of DNA-based COVID-19 vaccine
08/12/2020 03:36
TOKYO, Dec 8 (Reuters) - Japanese biotech company AnGes Inc
4563.T said on Tuesday it had initiated a phase 2/3 clinical
trial of its DNA-based COVID-19 vaccine candidate.
The study is taking place at eight facilities in eastern and
western Japan involving 500 test subjects, the company said in a
statement. urn:newsml:reuters.com:*:nL4N2DN0GU
(Reporting by Rocky Swift; Editing by Kim Coghill)
((rocky.swift@thomsonreuters.com;))
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001